Sheela Upadhyaya | Assoc. Director Highly Specialised Technologies
National Institute For Health and Care Excellence

Sheela Upadhyaya, Assoc. Director Highly Specialised Technologies, National Institute For Health and Care Excellence

Sheela Upadhyaya is currently the Associate Director of the Highly Specialised Technology program at NICE and is responsible for running the program to evaluate medicines and technologies for rare and ultra-rare conditions for commissioning in the NHS.

Prior to joining NICE, she was responsible for commissioning rare and ultra-orphan disease services in NHS England, where she delivered many improvements to these services by collaborating with industry, clinicians and patient groups. She held the position of national lead for lysosomal storage disorders and the Extra Corporeal Membrane (ECMO) service for adults working closely with ITU centres in England to manage bed pressures and patient needs.  In addition, she successfully decommissioned failing services and seamlessly transferred the care of patients to better quality services.

As commissioner for the National Specialised Commissioning team, she held responsibility for the genetics and metabolic portfolio leading nationally for lysosomal storage disorders.  In this role she delivered more efficient drug and homecare prices by running national tender exercises with the Department of Health, Commercial Medicines Unit.  As a result of this, she was selected to sit on the Department of Health’s National Homecare Medicines Committee developing the national homecare standards. Sheela has a passion for partnership working believes that collaboration across the sector is the key to delivering high quality results. Mrs Upadhyaya was nominated for a “Compact Award” in recognition of her patient engagement activity. She strives to ensure services for patients with rare conditions provide excellent quality and good outcomes in an efficient effective environment.


Day 1 Orphan 14th Nov @ 09:00

Plenary discussion: ORPH-VAL Using best practice European principles in assessing the value of orphan medicines: Correcting the discrepancy between countries

  • How do these principles compare to the criteria that current countries use?
  • Opportunity for different European payers/HTAs to openly suggest what is realistic and why
  • Creating a harmonised and sustainable model adapted to rare diseases
  • How is it acceptable that each country has a different post marketing criteria?
  • What are the interests of payers and HTA bodies when considering how to improve access to rare disease therapies?
More panellists to be confirmed shortly:
Senior representative HTA/payer, Italy
Senior representative HTA/payer, France

Day 1 Orphan 14th Nov @ 14:20

How will the new Highly specialised technology (HST) methods from NICE change the way you prepare?

back to speakers